Cyprotex (LSE:CRX) EBIT : £-2.43 Mil (TTM As of Jun. 2016)

View and export this data going back to 2002. Start your Free Trial

What is Cyprotex EBIT?

Cyprotex's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2016 was £3.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was £-2.43 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cyprotex's annualized ROC % for the quarter that ended in Jun. 2016 was 32.51%. Cyprotex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was 95.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cyprotex's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -6.72%.

Cyprotex EBIT Historical Data

The historical data trend for Cyprotex's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex EBIT Chart

Cyprotex Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

EBIT

Get a 7-Day Free Trial

0.67

0.33

-0.97

-3.48

-6.07

Cyprotex Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16
EBIT	Get a 7-Day Free Trial															-0.19	-3.29	-0.16	-5.92	3.49

Competitive Comparison of Cyprotex's EBIT

For the Biotechnology subindustry, Cyprotex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyprotex's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyprotex's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cyprotex's EV-to-EBIT falls into.

Cyprotex EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2016 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-2.43 Mil.

Cyprotex (LSE:CRX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cyprotex's annualized ROC % for the quarter that ended in Jun. 2016 is calculated as:

	ROC % (Q: Jun. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2015 )	+	Invested Capital (Q: Jun. 2016 ))	/ count )
=	2.99 * ( 1 - 9% )	/	( (8.465	+	8.276)	/ 2 )
=	2.7209	/	8.3705
=	32.51 %

where

	Invested Capital		(Q: Dec. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.466	-	1.591	-	( 5.41	-	max(0, 1.832	-	10.117	+	5.41	))
=	8.465

	Invested Capital		(Q: Jun. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	16.492	-	1.398	-	( 6.818	-	max(0, 1.602	-	11.065	+	6.818	))
=	8.276

Note: The Operating Income data used here is two times the semi-annual (Jun. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

Cyprotex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2016 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2015		Q: Jun. 2016
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	6.972	/	( ( (4.137 + max(3.085, 0))	+	(4.531 + max(2.848, 0)) )	/	2 )
=	6.972	/	( ( 7.222	+	7.379 )	/	2 )
=	6.972	/	7.3005
=	95.50 %

where Working Capital is:

	Working Capital		(Q: Dec. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.018	+	0.861	+	0.828)	-	(1.591	+	0	+	0.031)
=	3.085

	Working Capital		(Q: Jun. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.531	+	0.905	+	0.811)	-	(1.398	+	0	+	0.0010000000000001)
=	2.848

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cyprotex's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2016 )
	=	-2.429	/	36.127
	=	-6.72 %

Cyprotex EBIT Related Terms

Thank you for viewing the detailed overview of Cyprotex's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyprotex (LSE:CRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cyprotex.com

Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines